Product Description
Timolumab (BTT-1023; SI-3106; SI-636) is a fully human, monoclonal, anti-vascular adhesion protein1 (VAP-1) antibody which works by blocking the adhesion function of VAP-1 which diminishes leucocyte entry to sites of inflammation.
Mechanisms of Action: AOC3 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Acorda
Company Location: ARDSLEY NY 10502
Company CEO: Ron Cohen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Cholangitis, Sclerosing
Phase 1: Arthritis, Rheumatoid|Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BUTEO: A clinical trial of BTT1023 in patients with PSC | P2 |
Completed |
Cholangitis, Sclerosing |
2018-10-23 |
|
| BUTEO | P2 |
Completed |
Cholangitis, Sclerosing |
2018-10-23 |
|
| BTT12-CD016 | P1 |
Completed |
Psoriasis |
2010-08-01 |
|
| BTT12-CD015 | P1 |
Completed |
Arthritis, Rheumatoid |
2009-11-01 |